This cohort study evaluates the risks of neonatal adverse events after exposure to COVID-19 vaccination during pregnancy.
Introduction: Although over 100 million pregnant women worldwide are at risk of infection with SARS-CoV-2, little data exists on the impact of COVID-19 and related treatments on maternal/neonatal health. Objectives: 1) To quantify the prevalence of medication use in pregnancy ...
Despite being at higher risk of severe disease and pregnancy complications, evidence on susceptibility to SARS-CoV-2 infection in pregnancy is still limited. The aim of the study is to compare the likelihood of undergoing a SARS-CoV-2 test and testing positive for COVID-19 in pregnancy and ...
This cohort study assesses whether obstetric outcomes and pregnancy-related complications changed during the COVID-19 pandemic.
Infants born to women who had COVID-19 during pregnancy were more likely to receive a neurodevelopmental diagnosis in the first year after delivery208. A paediatric long COVID centre’s experience treating patients suggests that adolescents with a moderate to severe form of long COVID have ...
Sub-analyses were conducted to characterise incomplete vaccine schedule in pregnancy. Analyses were restricted to women aged 18–55 years at the time of their first COVID-19 vaccine. Women were only entered into the cohort if they received their first vaccine dose after 16 April 2021. Prior to...
risks of acute pulmonary embolism, myocarditis and cardiomyopathy, venous thromboembolic events, acute and unspecified renal failure, and type 1 diabetes207. Infants born to women who had COVID-19 during pregnancy were more likely to receive a neurodevelopmental diagnosis in the first year after ...
For CoronaVac, contraindications include a history of allergic reactions, severe underlying conditions, pregnancy, or lactation. We retrieved the records of patients who received inpatient or outpatient services provided by the HA between 1 January 2018 and 31 July 2021, and selected those ever coded...
COVID-19 related deaths were obtained from the NCIMS record. Information on sociodemographic characteristics, smoking, pregnancy and selected co-morbidities was ob- tained from the NCIMS based on the initial interview and subsequent case interviews. Additional comorbidity information was obtained via ...
Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464. doi:10.1056/NEJMoa2216480 PubMedGoogle ScholarCrossref 31. FDA approves new drug to prevent RSV in babies and toddlers. US Food and Drug Administration. July 18, ...